Market Cap
$34.0B
ALNY
ALNYLAM PHARMACEUTICALS, INC.
$231.18 ▼ -6.31%
Prev close $246.74Market cap$34.0B
ConsensusBuy
12-mo target$371.12 (+60.5%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (5 insiders)High Impact Filing (7/10)29 New Institutional Positions21 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on ALNY right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (76%)
Inst. Holders
50 funds
Inst. Value
$32.5B
Inst. Activity
29 buys / 21 sells
Insider Activity
$0.00 buy / $3.4M sell
Insider Net $
-$3.4M
SEC Reports
6
Congressional
1 trades
Price chart 30d -13.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: ALNY — 59.1% short (0.6M / 1.0M)
Short: 578,562 | Exempt: 126 | TRF Vol: 978,710 | Short Ratio: 59.1% | Off-exchange volume (dark poo
Sep 19, 2026 Insider
Aug 19, 2026 SEC Greenstreet Yvonne was granted 107 shares
Chief Executive Officer
A Markman claim construction ruling in a patent case brought by the University of Texas against Alnylam over its drug ON
COURT-RULING — Impact 4/10
Aug 17, 2026 Event
The Board of Regents of the University of Texas System v. Alnylam Pharmaceuticals Inc. et al
Court ruling (mad) — Docket: 1:25-cv-13865
Aug 11, 2026 Congress
Jul 30, 2026 SEC Cory Booker sell
$1,001 - $15,000 — Senate
Alnylam reported Q2 2026 non-GAAP diluted EPS of $1.84 (missed consensus of $2.15 by 14.5%) and total revenue of $1.291B
8-K — Impact 7/10
Four institutional asset managers increased their ALNY positions in Q2 2026, led by Robeco Institutional Asset Managemen
INST-CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO — TRIM
2,675,517 shares ($785.3M)
Analyst ratings buy % +1.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
76% rate it Buy or better · 38 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Sep 21, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 8, 2026 | Jefferies | MAINTAIN | Hold | 53% |
| Sep 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 19, 2026 | BMO Capital | INITIATE | Outperform | 53% |
| Aug 14, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Aug 4, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 3, 2026 | Raymond James | UPGRADE | Strong Buy | 54% |
| Aug 3, 2026 | Citigroup | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 20 | 9 | 0 | 0 | 76% | |
| Aug 1, 2026 | 8 | 21 | 8 | 0 | 0 | 78% | |
| Jul 1, 2026 | 8 | 21 | 9 | 0 | 0 | 76% | |
| Jun 1, 2026 | 7 | 21 | 9 | 0 | 0 | 76% | |
| May 1, 2026 | 7 | 20 | 9 | 0 | 0 | 75% | |
| Apr 1, 2026 | 7 | 20 | 9 | 0 | 0 | 75% | |
| Mar 1, 2026 | 8 | 20 | 8 | 0 | 0 | 78% | |
| Feb 1, 2026 | 8 | 19 | 9 | 0 | 0 | 75% |
Price targets
Where 26 covering analysts think ALNY trades over the next 12 months.
$371.12 +60.5% upside Strong Buy
Current$231.18 Low$256.00 Median$350.00 High$536.00 26 analysts
$256.00$536.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 3 neutral · avg impact 4.7/10.
NEUTRALCOURT-RULING4/10
A Markman claim construction ruling in a patent case brought by the University of Texas against Alny
Aug 19, 2026
BEARISH8-K7/10
Alnylam reported Q2 2026 non-GAAP diluted EPS of $1.84 (missed consensus of $2.15 by 14.5%) and tota
Jul 30, 2026
BULLISHINST-CLUSTER4/10
Four institutional asset managers increased their ALNY positions in Q2 2026, led by Robeco Instituti
Jul 29, 2026
NEUTRALCLUSTER3/10
Seven Alnylam Pharmaceuticals insiders executed trades over the past week, with three C-suite execut
Mar 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: ALNY — 59.1% short (0.6M / 1.0M)
Short: 578,562 | Exempt: 126 | TRF Vol: 978,710 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
short_volume
Short Volume: ALNY — 77.0% short (0.4M / 0.5M)
Short: 388,483 | Exempt: 0 | TRF Vol: 504,344 | Short Ratio: 77.0% | Off-exchange volume (dark pool + OTC)
Sep 18, 2026
short_volume
Short Volume: ALNY — 73.5% short (0.5M / 0.6M)
Short: 460,290 | Exempt: 0 | TRF Vol: 626,322 | Short Ratio: 73.5% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
short_volume
Short Volume: ALNY — 74.0% short (0.5M / 0.6M)
Short: 478,400 | Exempt: 11,931 | TRF Vol: 646,297 | Short Ratio: 74.0% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
short_volume
Short Volume: ALNY — 74.6% short (0.5M / 0.6M)
Short: 457,715 | Exempt: 51 | TRF Vol: 613,919 | Short Ratio: 74.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.31 | $1.94–$3.45 | -20.3% | -0.2% | 2↑ 11↓ | $1.4B | 14 |
| Next Q | $2.71 | $1.72–$3.43 | 116.5% | -2.7% | 5↑ 9↓ | $1.6B | 14 |
| Current FY | $8.83 | $7.77–$10.71 | 73.9% | -0.9% | 5↑ 10↓ | $5.5B | 14 |
| Next FY | $12.42 | $8.63–$17.74 | 40.6% | -1.3% | 4↑ 11↓ | $6.9B | 14 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.311 | — |
| 7d ago | $2.315 | -0.005 |
| 30d ago | $2.315 | -0.005 |
| 60d ago | $2.315 | -0.005 |
| 90d ago | $2.435 | -0.125 |
Institutional ownership
Which big funds own ALNY (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $32.5B total value (108,158,010 shares) as of 2026-Q2. Top holders: FMR, Capital, BlackRock,. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 15,023,962 | $4.5B | 13.9% | — |
| Capital World Investors | 11,144,846 | $3.4B | 10.3% | — |
| BlackRock, Inc. | 10,907,675 | $3.3B | 10.1% | — |
| Capital Research Global Investors | 9,750,699 | $2.9B | 9.0% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,538,390 | $2.0B | 6.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,029,478 | $1.8B | 5.6% | — |
| Invesco Ltd. | 3,754,318 | $1.1B | 3.5% | — |
| STATE STREET CORP | 3,555,689 | $1.1B | 3.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,635,840 | $791.3M | 2.4% | — |
| JPMORGAN CHASE & CO | 2,675,517 | $785.3M | 2.4% | TRIM -57.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | TRIM | 6,323,752 | 2,675,517 | -57.7% | $785.3M |
| NORGES BANK | NEW | — | 2,271,813 | — | $683.9M |
| Orbis Allan Gray Ltd | ADD | 1,334,825 | 1,987,407 | +48.9% | $598.3M |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 662,365 | 893,795 | +34.9% | $269.1M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 88,278 | 729,635 | +726.5% | $219.6M |
| UBS Group AG | ADD | 458,870 | 627,004 | +36.6% | $188.7M |
| Polar Capital Holdings Plc | ADD | 257,674 | 482,751 | +87.3% | $145.3M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | TRIM | 496,004 | 350,560 | -29.3% | $105.5M |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 208,938 | 334,246 | +60.0% | $100.6M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 447,887 | 316,001 | -29.4% | $95.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 50 transactions. Net -$3.4M — $0.00 bought, $3.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 19, 2026 | Greenstreet Yvonne | Chief Executive Officer | AWARD | 107 | — | — |
| Jun 1, 2026 | PYOTT DAVID E I | Director | SELL | 17 | $302.65 | $5.1K |
| Jun 1, 2026 | PYOTT DAVID E I | Director | SELL | 495 | $300.72 | $148.9K |
| Jun 1, 2026 | PYOTT DAVID E I | Director | SELL | 1,175 | $298.91 | $351.2K |
| Jun 1, 2026 | PYOTT DAVID E I | Director | SELL | 1,222 | $299.87 | $366.4K |
| Jun 1, 2026 | Cravatt Benjamin | Director | AWARD | 4,393 | — | — |
| Jun 1, 2026 | PYOTT DAVID E I | Director | EXERCISE | 3,830 | — | — |
| Jun 1, 2026 | PYOTT DAVID E I | Director | SELL | 921 | $297.71 | $274.2K |
| May 20, 2026 | Arbuckle Stuart A | Director | AWARD | 671 | — | — |
| May 20, 2026 | Arbuckle Stuart A | Director | AWARD | 1,441 | — | — |
Congressional trades
ALNY trades disclosed by members of Congress, with disclosure delay.
1 members · 0 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | Cory Booker | D | SENATE | SELL | $1,001 - $15,000 | Alnylam Pharmaceuticals Inc | Sep 9, 2026(30d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ALNY.
Shares short
7,194,097
Settlement Sep 15, 2026
Change vs prior
+13.5%
Semi-monthly cycle
Days to cover
4.1
At avg daily volume
Of shares outstanding
≈5.4%
Estimate — not % of float
All ALNY filing & press-release reports (6)
- COURT-RULING reportAug 19, 2026
- 8-K reportJul 30, 2026
- INST-CLUSTER reportJul 29, 2026
- CLUSTER reportMar 6, 2026
- CLUSTER reportMar 5, 2026
- INST-CLUSTER reportFeb 28, 2026